Palatin completes study enrolment of bremelanotide plus tirzepatide to treat obesity
Palatin Technologies has completed enrolment in the study entitled "BMT-801, A Phase II, Randomized, Double-Blind, Placebo-Controlled,...
top of page
Browse by category
Search
Palatin initiates study of bremelanotide for the treatment of obesity
Palatin Technologies has begun a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate...
Palatin to investigate MC4R agonist as a potentially effective and safe treatment for obesity
Palatin Technologies, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of...
Browse by tag
bottom of page